Clinical Trial Update: Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of dasatinib in patients with early chronic phase chronic myeloid leukemia has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2026-01-15